超7000万融资！神经科技初创企业完成种子轮

Core Insights - Coherence Neuro, a UK-based neurotechnology startup, has raised approximately $10 million in seed funding to advance its brain-computer interface (BCI) platform for cancer treatment [2] - The company aims to utilize BCI technology, traditionally used for motor disorders and rehabilitation, for cancer diagnosis, monitoring, and intervention, proposing "electricity" as a fourth treatment modality alongside traditional methods [2][3] Company Overview - Founded in 2023 and headquartered in London, Coherence Neuro's founding team includes researchers from prestigious institutions such as Cambridge University and Stanford University [3] - The mission of the company is to decode the "electrical language" between cancer and the nervous system, focusing on the abnormal electrical signals in the neuro-immune network associated with tumors [3] Product Introduction - The core product, SOMA series implantable neural interface platform (SOMA-1), aims to record and modulate cancer-related electrophysiological signals [4] - Coherence Neuro introduces the concept of "Disease-Computer Interface" to achieve real-time understanding and intervention of disease states through decoding electrical signals from tumors and surrounding neural systems [4] Treatment Framework - Coherence Neuro identifies electricity as the fourth pillar of cancer treatment, introducing "Bioelectronic Therapy" with three main modes: 1. Targeted Electrotherapy, which disrupts malignant cell stability through direct electrical stimulation [8] 2. Immunomodulation, enhancing anti-tumor immune responses via precise stimulation of the vagus nerve [9] 3. Neuromodulation, which suppresses tumor growth by regulating supportive neural structures [10] Device and Platform Architecture - SOMA-1 features a closed-loop architecture for integrated monitoring, computation, and intervention, allowing for AI-driven optimization of stimulation parameters [7] - The device is designed for long-term stability and compatibility with various neural sites, while the AI signal decoding engine enables real-time tracking of cancer electrical signals [13] Clinical Development - Coherence Neuro has completed animal testing and plans to enter human clinical trials in 2025, targeting treatment-resistant tumors such as glioblastoma, triple-negative breast cancer, and pancreatic ductal adenocarcinoma [15] - The approach focuses on electrophysiological mechanisms rather than genetic mutations, potentially allowing for broader cancer treatment applications [16] Industry Impact - Coherence Neuro represents a shift in the medical device industry from "assisted medical" to "active treatment," emphasizing the integration of biological and electronic technologies [17] - The company's innovations may redefine cancer treatment paradigms, positioning electrical therapy alongside immunotherapy and targeted treatments as a new cornerstone in oncology [17]